Galapagos to exit cell therapy, with loss of 365 jobs and global sites to shutternews2025-10-21T10:56:09+00:00October 21st, 2025|Endpoints News|
‘Decade of the ADCs’ continues as AstraZeneca, Kelun and Merck present data at #ESMO25news2025-10-21T09:15:27+00:00October 21st, 2025|Endpoints News|
Summit plans to take ivonescimab to FDA, even with subpar OS datanews2025-10-20T19:05:12+00:00October 20th, 2025|Endpoints News|
#ESMO25: Roche says ctDNA-guided Tecentriq prolonged survival in bladder cancer patientsnews2025-10-20T15:10:59+00:00October 20th, 2025|Endpoints News|
RAPT, Jeyou are itching to start Phase 3 after encouraging mid-stage results in urticarianews2025-10-20T15:04:55+00:00October 20th, 2025|Endpoints News|
#ESMO25: Novartis seeks to move Pluvicto to earlier prostate cancer, but data underwhelmnews2025-10-20T14:37:56+00:00October 20th, 2025|Endpoints News|
#ESMO25: Iambic Therapeutics gives first clinical readout for AI-designed cancer drugnews2025-10-20T11:00:14+00:00October 20th, 2025|Endpoints News|
#ESMO25: Ideaya’s drug saves almost 60% of eye cancer patients from surgery in Phase 2 trialnews2025-10-20T09:48:53+00:00October 20th, 2025|Endpoints News|
#ESMO25: Exelixis says TKI extended survival in Phase 3 colorectal cancer trial news2025-10-20T06:30:48+00:00October 20th, 2025|Endpoints News|
#ESMO25: Sanofi, Orano Med’s radiopharmaceutical looks competitive in rare cancernews2025-10-20T06:30:11+00:00October 20th, 2025|Endpoints News|
